ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221 CHF | +1.01% |
|
-0.50% | -9.61% |
| 04-26 | Roche: positive CHMP opinion for Alecensa | CF |
| 04-26 | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
Chart calendar Roche Holding AG
008e510bb3e9710.bo32q6_U0e2fKocu4e5psJHoYAoAVuksYV5WpNyycNo.Gvii6vqcltTtGvIemd0ggNuGEm1KLLZYBjUUk_HVSa9XxrKSl4WngNh_8A~b922a285ff98558ffa1178c664ce7504
Upcoming events on Roche Holding AG
Past events on Roche Holding AG
| 24/04/2024 13:00 | Q1 2024 Sales and Revenue Call |
| 24/04/2024 06:00 | Q1 2024 Sales and Revenue Release |
| 26/03/2024 08:00 | BNP Exane Healthcare Conference |
| 21/03/2024 08:00 | Kepler Cheuvreux Swiss Seminar |
| 13/03/2024 | Ex-dividend day for final dividend |
| 12/03/2024 14:00 | Barclays Global Healthcare Conference |
| 12/03/2024 09:30 | Annual General Meeting |
| 11/03/2024 14:00 | Investor Meeting - Neurology |
| 10/03/2024 | HIMSS Conference |
| 06/03/2024 15:00 | TD Cowen Health Care Conference |
| 27/02/2024 08:00 | UBS European Healthcare Conference |
| 24/02/2024 | American Academy of Allergy, Asthma & Immunology Meeting |
| 22/02/2024 17:00 | Citi Oncology Leadership Summit |
| 01/02/2024 13:00 | Q4 2023 Earnings Call |
| 01/02/2024 06:00 | Q4 2023 Earnings Release |
| 11/01/2024 09:00 | Octavian Seminar |
| 09/01/2024 16:00 | JPMorgan Healthcare Conference |
| 12/12/2023 17:00 | American Society of Hematology Meeting |
| 12/12/2023 07:00 | BNPP Exane DILS CEO Conference |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number: #4090 |
Past dividends on Roche Holding AG
| 13/03/2024 | Annual 9.6 CHF |
| 15/03/2023 | Annual 9.5 CHF |
| 16/03/2022 | Annual 9.3 CHF |
| 17/03/2021 | Annual 9.1 CHF |
| 18/03/2020 | Annual 9 CHF |
| 06/03/2019 | Annual 8.7 CHF |
| 14/03/2018 | Annual 8.3 CHF |
| 15/03/2017 | Annual 8.2 CHF |
| 02/03/2016 | Annual 8.1 CHF |
| 04/03/2015 | 8 CHF |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million CHF | Released Forecast Spread | 61 466 61 789 -0.52% | 58 323 59 276 -1.61% | 62 801 62 237 0.91% | 63 281 63 332 -0.08% | 58 716 59 502 -1.32% | 60 042 |
|
EBITDA Million CHF | Released Forecast Spread | 25 419 24 199 5.04% | 24 281 24 532 -1.02% | 24 692 25 569 -3.43% | 25 015 24 644 1.51% | 21 976 22 765 -3.46% | 22 783 |
|
EBIT Million CHF | Released Forecast Spread | 22 479 22 680 -0.89% | 21 536 21 622 -0.4% | 21 897 22 784 -3.89% | 22 173 22 200 -0.12% | 19 240 19 957 -3.59% | 20 179 |
|
Earnings before Tax (EBT) Million CHF | Released Forecast Spread | 16 614 18 369 -9.56% | 17 965 18 289 -1.77% | 17 398 20 328 -14.41% | 16 327 19 694 -17.1% | 14 079 17 867 -21.2% | 18 112 |
|
Net income Million CHF | Released Forecast Spread | 13 497 14 257 -5.33% | 14 295 14 335 -0.28% | 13 930 15 065 -7.53% | 12 421 14 442 -13.99% | 11 498 13 584 -15.35% | 13 314 |
|
EPS CHF | Released Forecast Spread | 15,6 16,6 -5.73% | 16,5 16,5 -0.02% | 16,2 17,8 -9.22% | 15,4 17,9 -14.08% | 14,3 17,0 -15.74% | 17,0 |
| Announcement Date | 30/01/20 | 04/02/21 | 03/02/22 | 02/02/23 | 01/02/24 | - |
Quarterly results
| Fiscal Period | December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2023 S2 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million CHF | Released Forecast Spread | 30 997 31 426 -1.37% | 29 281 30 369 -3.58% | 29 042 30 037 -3.31% | 30 713 30 038 2.25% | 16 117 15 745 2.36% | 32 088 31 791 0.93% | 16 445 16 072 2.32% | 15 850 15 474 2.43% | 32 295 31 869 1.34% | 14 742 15 274 -3.48% | 16 244 16 102 0.88% | 30 986 30 807 0.58% | 15 322 15 011 2.07% | 14 457 14 534 -0.53% | 29 779 29 914 -0.45% | 14 274 14 256 0.13% | 14 938 | 28 937 29 318 -1.3% | 14 399 14 370 0.21% | 14 540 | 29 055 | 14 690 | 15 015 | 29 705 | 15 320 | 30 630 | 30 615 |
|
EBIT Million CHF | Released Forecast Spread | 10 116 10 525 -3.89% | 11 766 11 824 -0.49% | 9 770 9 915 -1.46% | 11 652 11 715 -0.53% | 10 245 11 539 -11.21% | 12 668 12 024 5.35% | 9 505 9 639 -1.39% | 10 911 11 057 -1.32% | 8 329 9 168 -9.15% | 10 443 | 9 916 | ||||||||||||||||
|
Earnings before Tax (EBT) Million CHF | Released Forecast Spread | 6 260 9 758 -35.85% | 10 181 10 632 -4.24% | 7 784 9 124 -14.68% | 9 887 10 773 -8.22% | 7 511 10 155 -26.04% | 10 985 11 047 -0.56% | 5 342 9 016 -40.75% | 9 174 10 510 -12.71% | 4 905 8 786 -44.17% | 9 047 | 9 593 | ||||||||||||||||
|
Net income Million CHF | Released Forecast Spread | 4 878 6 896 -29.26% | 8 079 8 713 -7.27% | 6 216 7 084 -12.25% | 7 803 8 526 -8.48% | 6 127 7 703 -20.46% | 8 530 8 216 3.82% | 3 891 6 862 -43.3% | 7 137 7 896 -9.61% | 4 361 6 781 -35.69% | 6 723 | 7 251 | ||||||||||||||||
|
EPS CHF | Released Forecast Spread | 5,63 7,56 -25.53% | 9,32 9,70 -3.92% | 7,20 8,06 -10.64% | 9,05 9,29 -2.58% | 7,15 9,30 -23.12% | 10,5 10,0 5.14% | 4,83 7,87 -38.6% | 8,87 9,42 -5.81% | 5,44 8,43 -35.47% | 8,37 | 9,04 | ||||||||||||||||
| Announcement Date | 30/01/20 | 23/07/20 | 04/02/21 | 22/07/21 | 03/02/22 | 03/02/22 | 25/04/22 | 21/07/22 | 21/07/22 | 18/10/22 | 02/02/23 | 02/02/23 | 27/04/23 | 27/07/23 | 27/07/23 | 01/11/23 | - | 01/02/24 | - | - | - | - | - | - | - | - | - |
More events
Past sector events for Roche Holding AG
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ROG Stock
- Calendar Roche Holding AG
